Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Blood Advances|2022Cited by 52
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Yan Xu et al.|Targeted Oncology|2023Cited by 46
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabMarie‐Emilie Willemin, Suzette Girgis, Shun Xin Wang Lin et al.|CPT Pharmacometrics & Systems Pharmacology|2024Cited by 6
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.Suzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Journal of Clinical Oncology|2021Cited by 5
Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple MyelomaXin Miao, Honghui Zhou, Liviawati S. Wu et al.|Blood|2022Cited by 5